Pharmaceutical giant AbbVie is reportedly in advanced negotiations to acquire Revolution Medicines, a biotechnology firm specializing in targeted cancer therapies. The news, first reported by the Wall Street Journal on Wednesday, January 7, 2026, has sent ripples through the healthcare sector as AbbVie continues its aggressive expansion into precision oncology.
Market Reaction and Valuation
Following the report, shares of Revolution Medicines skyrocketed by nearly 30%, briefly halting trade due to volatility. AbbVie’s stock also saw a healthy climb of over 5% as investors signaled approval for the potential merger.
While official financial terms have not been disclosed, analysts point to several key valuation metrics:
- Current Market Value: Revolution Medicines was valued at approximately $16 billion prior to the surge.
- Estimated Deal Price: Including a standard acquisition premium, the final price tag could reach $20 billion or more.
- Timeline: Sources suggest a formal agreement could be finalized imminently, provided negotiations proceed without last-minute obstacles.
Addressing the “Humira” Revenue Gap
This potential deal is a strategic move for AbbVie, which has been seeking new revenue streams since its flagship drug, Humira, lost patent protection. To counter declining sales of the blockbuster arthritis treatment, AbbVie has spent more than $20 billion on acquisitions since 2023.
By adding Revolution Medicines to its portfolio, AbbVie would gain access to a cutting-edge pipeline of RAS-targeted therapies. These treatments are designed to inhibit specific growth pathways in difficult-to-treat cancers, positioning AbbVie at the forefront of the precision medicine market.
Impact on the Biotech Sector
The news of the AbbVie-Revolution talks has triggered a broader rally across the oncology space. Other companies focusing on similar cancer pathways saw significant gains:
- Erasca (ERAS): Surged by 66%.
- Verastem (VSTM): Rose by 25%.
- Tango Therapeutics (TNGX): Climbed 20%.
As of Wednesday afternoon, neither AbbVie nor Revolution Medicines has issued an official statement regarding the acquisition talks.
READ ALSO: Ethiopia Marks Orthodox Christmas Eve with Grand Candlelit Ceremony
